Form 4: Outlook Therapeutics Director Kurt Hilzinger Acquires Stock Options

Director Kurt Hilzinger acquired 94,441 stock options in Outlook Therapeutics, Inc. on March 7, 2024.

Summary

• On March 7, 2024, Kurt J Hilzinger, a director of Outlook Therapeutics, Inc., acquired 94,441 stock options.
• The options were granted under the company's 2015 Equity Incentive Plan.
• The exercise price of the options is $0.41.
• The options will fully vest on the earlier of March 7, 2025, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service.
• The options are subject to acceleration upon a Change in Control, provided the Reporting Person provides continuous service immediately prior to such Change in Control.
• The expiration date of the options is March 7, 2034.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain information that would significantly sway investor sentiment positively or negatively. It's a neutral event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Regeneron, Amgen, and Biogen also utilize stock options to incentivize their directors and officers.
• The vesting schedule and terms of the options appear to be standard within the industry.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in the best interests of the shareholders.
• Employees may view the option grant as a positive sign of the company's commitment to its leadership.

Key Dates